John Teerlink
Internal Medicine · San Francisco, CANPI 1851309975
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $587,269 of the $819,023 with a category attached, or 71.7%. 27 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 50.8% of the total. Reporting peaked in 2020 at $351,819 and has fallen 82.8% since, to $60,473 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $2481.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$416K
- Astrazeneca UK Limited$103K
- Amgen$37K
- Boehringer Ingelheim Pharma GmbH & Co.kg$33K
- Eli Lilly$26K
- Regeneron$18K
- plus $186K from 21 others
Across 19 payments — averaging $6686.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$123K
- Eli Lilly$4K
- Amgen$151
What the payments were for
- Consulting fees$587,26972%
- Speaking & faculty fees$43,0415%
- Travel & lodging$181,58422%
- Food & beverage$7,1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 134 | $415,758 |
| Astrazeneca UK Limited | 27 | $103,277 |
| Amgen | 38 | $36,952 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 5 | $32,793 |
| Eli Lilly | 12 | $26,000 |
| Regeneron | 19 | $17,900 |
| Edwards Lifesciences | 9 | $14,159 |
| E.r. Squibb & Sons, L.L.C. | 14 | $13,821 |
| Travere Therapeutics, Inc. | 3 | $13,052 |
| Astrazeneca AB | 3 | $12,893 |
| AstraZeneca | 10 | $12,889 |
| Abbott | 17 | $12,345 |
| Novartis | 1 | $11,088 |
| Medtronic | 2 | $9,774 |
| Impulse Dynamics (USA) Inc. | 7 | $9,495 |
| Novo Nordisk | 1 | $9,300 |
| GSK | 1 | $9,000 |
| Merck | 6 | $8,784 |
| Intercept Pharmaceuticals, Inc. | 1 | $8,625 |
| BD | 1 | $7,500 |
| Neovasc Medical Inc | 1 | $6,750 |
| Scpharmaceuticals Inc. | 3 | $5,600 |
| Livanova USA, Inc. | 8 | $5,250 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $4,778 |
| American Regent | 1 | $4,320 |
| Daiichi Sankyo Inc. | 2 | $4,050 |
| Bayer | 1 | $2,871 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$422,633
- EMPAGLIFLOZIN$27,062
- OPTIMIZER$18,759
- ENTRESTO$11,088
- INJECTAFER$8,370
- LUTONIX$7,500
- FARXIGA$6,251
- MK-1242$5,650
- FUROSCIX$5,600
- MOUNJARO$5,200
- VNS Therapy$3,750
- Kerendia$2,871
- CardioMEMS HF System$1,657
- VNS - Vitaria$1,500
- PRADAXA$215
How this compares
$819,023 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
- Riley BoveSan Francisco$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.